Results 231 to 240 of about 123,913 (326)

Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients. [PDF]

Acta Neurochir (Wien)
Ryba A, Gonzalez Lopez D, Rotermund R, Flitsch J.   +3 more
europepmc   +1 more source

Dopamine Agonist-Induced Cerebrospinal Fluid Rhinorrhoea: A Case Report. [PDF]

J Cancer Allied Spec, 2021
Irfan H, Siddiqi AI, Azmat U, Shafiq W, Yousaf I, Naveed MA.   +5 more
europepmc   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Cabergoline, Dopamine D2 Receptor Agonist, Prevents Neuronal Cell Death under Oxidative Stress via Reducing Excitotoxicity

, 2014
Haruki Odaka, Tadahiro Numakawa, Naoki Adachi, Yoshiko Ooshima, Shingo Nakajima, Yusuke Katanuma, Takafumi Inoue, Hiroshi Kunugi   +7 more
openalex   +2 more sources

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease. [PDF]

Eur J Neurol
Staubo SC, Fuskevåg OM, Toft M, Lie IH, Alvik KMJ, Jostad P, Tingvoll SH, Lilleng H, Rosqvist K, Størset E, Odin P, Dietrichs E, Dietrichs ES.   +12 more
europepmc   +1 more source

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease. [PDF]

Mov Disord, 2021
Picillo M, Phokaewvarangkul O, Poon YY, McIntyre CC, Beylergil SB, Munhoz RP, Kalia SK, Hodaie M, Lozano AM, Fasano A.   +9 more
europepmc   +1 more source

Dopamine Agonists and Impulse Control Disorders: A Complex Association [PDF]

, 2017
Marie Grall‐Bronnec, Caroline Victorri‐Vigneau, Yann Donnio, Juliette Leboucher, Morgane Rousselet, Elsa Thiabaud, Nicolas Zreika, Pascal Derkinderen, Gaëlle Challet‐Bouju   +8 more
openalex   +1 more source

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease. [PDF]

CNS Neurol Disord Drug Targets
Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S.   +5 more
europepmc   +1 more source

Pharmacokinetics and adverse effects of a long‐acting IM dopamine agonist: Cabergoline in healthy horses

Equine Veterinary Education, EarlyView.
Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess, A. Bracken, S. Rao, Y. Nout‐Lomas, D. Gustafson, L. Bass   +5 more
wiley   +1 more source